Clinically Bharat

Healthcare

Liquidia challenges regulatory exclusivity for rival’s inhaled drug, ET HealthWorld

Email :105

London: Liquidia Corp has filed a legal challenge to the U.S. Food and Drug Administration’s decision to grant three-year exclusivity to United Therapeutics’ inhaled drug used to treat lung disorders, it said on Thursday.

The FDA on Monday granted regulatory exclusivity to United’s Tyvaso DPI, which delays traditional approval for Liquidia’s inhaled drug, yutrepia.

Tyvaso DPI and yutrepia are inhaled drugs used to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Liquidia filed the litigation in the district court of the District of Columbia.

(Reporting by Sneha S K; Editing by Mrigank Dhaniwala)

  • Published On Aug 22, 2024 at 04:37 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles


Scan to download App


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Post